Zevin Asset Management LLC Purchases 19,416 Shares of Novo Nordisk A/S (NYSE:NVO)

Zevin Asset Management LLC grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 47.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 60,708 shares of the company’s stock after purchasing an additional 19,416 shares during the quarter. Zevin Asset Management LLC’s holdings in Novo Nordisk A/S were worth $5,222,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of NVO. First National Trust Co boosted its holdings in Novo Nordisk A/S by 12.9% during the 4th quarter. First National Trust Co now owns 2,954 shares of the company’s stock valued at $254,000 after acquiring an additional 338 shares during the period. King Wealth Management Group purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $205,000. Aviso Financial Inc. boosted its holdings in Novo Nordisk A/S by 2.8% during the 4th quarter. Aviso Financial Inc. now owns 33,867 shares of the company’s stock valued at $2,913,000 after acquiring an additional 908 shares during the period. Parnassus Investments LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at about $51,072,000. Finally, Sustainable Growth Advisers LP boosted its holdings in Novo Nordisk A/S by 23.6% during the 4th quarter. Sustainable Growth Advisers LP now owns 5,340,803 shares of the company’s stock valued at $459,416,000 after acquiring an additional 1,021,498 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Up 1.8 %

NVO opened at $77.22 on Friday. The stock has a market cap of $346.54 billion, a PE ratio of 23.47, a PEG ratio of 0.90 and a beta of 0.42. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a 50 day moving average of $83.95 and a 200-day moving average of $103.24. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is 47.72%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on NVO shares. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, Morgan Stanley began coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Three analysts have rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.